Skip to main content

Boeing said Thursday that it petitioned the U.S. Department of Commerce and the U.S. International Trade Commission for investigations into subsidies and pricing of Bombardier’s C Series.

Jasper Juinen/Bloomberg

Bombardier and the federal government have rejected Boeing's claim in a complaint filed with the U.S. government that its Canadian rival has dumped its new C Series commercial jet into the United States at below cost.

"Bombardier structures its commercial dealings to ensure compliance with the laws and regulations of the jurisdictions in which we operate, including those issues raised by Boeing," the Montreal-based aircraft manufacturer said in an e-mailed statement.

The world's third-largest airplane maker said it spends about $3-billion (U.S.) annually with U.S. suppliers and employs about 7,000 people in dozens of facilities in both rail and aerospace across 17 states.

Story continues below advertisement

For subscribers: Bombardier officials arrested in Sweden on bribery suspicion involving rail-equipment deal

The Seattle-based competitor said Thursday that it petitioned the U.S. Department of Commerce and the U.S. International Trade Commission for investigations into subsidies and pricing of the C Series.

It is also seeking an order to be issued against the sale of the plane in the important American market.

Economic Development Minister Navdeep Bains said the government objects to the allegations and vowed to mount "a vigorous defence."

"We are confident that our programs are consistent with Canada's international obligations," he said in a statement.

Boeing said it asking the Trump administration to act "to end Bombardier's illegal and unfair business practices before it is too late to prevent significant harm to America's aerospace industry and thousands of good-paying aerospace jobs."

The aerospace giant said the threat against its suppliers will only grow as Bombardier increases the annual production rate of the C Series to between 90 and 120 airplanes by 2020.

Story continues below advertisement

It said more than $3-billion in government subsidies so far have allowed Bombardier to engage in "predatory pricing" for an aircraft that competes directly against its 737-700 and 737 MAX 7 airplanes.

Boeing claimed Bombardier has sold C Series planes that cost $33-million to produce for less than $20-million each and at prices below what it charged in Canada.

"It's selling the aircraft in the U.S. at prices that are millions lower than those that they're charging in Canada, which is the very definition of dumping," Boeing spokesman Daniel Curran said in an interview.

Boeing joins Brazil, which filed a similar complaint with the World Trade Organization at the urging of rival manufacturer Embraer.

Delta Air Lines will become the first U.S. C Series carrier after placing a firm order a year ago for 75 CS100 aircraft valued at $5.6-billion. It also has options for 50 more planes and can covert some of the aircraft to larger CS300s.

Air Canada followed by ordering 45 CS300s for $3.8-billion at list prices, plus options for 30 more planes.

Story continues below advertisement

Airlines typically pay much less than list prices and early buyers of new planes usually get low prices.

The latest challenge against Bombardier's largest aircraft came just days after the U.S. imposed preliminary duties of up to 24 per cent on softwood lumber imported from Canada.

With files from Peter Cameron in Toronto

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies